BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

598 related articles for article (PubMed ID: 16373399)

  • 1. A novel partial agonist of peroxisome proliferator-activated receptor-gamma (PPARgamma) recruits PPARgamma-coactivator-1alpha, prevents triglyceride accumulation, and potentiates insulin signaling in vitro.
    Burgermeister E; Schnoebelen A; Flament A; Benz J; Stihle M; Gsell B; Rufer A; Ruf A; Kuhn B; Märki HP; Mizrahi J; Sebokova E; Niesor E; Meyer M
    Mol Endocrinol; 2006 Apr; 20(4):809-30. PubMed ID: 16373399
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A selective peroxisome proliferator-activated receptor-gamma (PPARgamma) modulator blocks adipocyte differentiation but stimulates glucose uptake in 3T3-L1 adipocytes.
    Mukherjee R; Hoener PA; Jow L; Bilakovics J; Klausing K; Mais DE; Faulkner A; Croston GE; Paterniti JR
    Mol Endocrinol; 2000 Sep; 14(9):1425-33. PubMed ID: 10976920
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structural and biochemical basis for the binding selectivity of peroxisome proliferator-activated receptor gamma to PGC-1alpha.
    Li Y; Kovach A; Suino-Powell K; Martynowski D; Xu HE
    J Biol Chem; 2008 Jul; 283(27):19132-9. PubMed ID: 18469005
    [TBL] [Abstract][Full Text] [Related]  

  • 4. G Protein-coupled Receptor 40 (GPR40) and Peroxisome Proliferator-activated Receptor γ (PPARγ): AN INTEGRATED TWO-RECEPTOR SIGNALING PATHWAY.
    Wang S; Awad KS; Elinoff JM; Dougherty EJ; Ferreyra GA; Wang JY; Cai R; Sun J; Ptasinska A; Danner RL
    J Biol Chem; 2015 Aug; 290(32):19544-57. PubMed ID: 26105050
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A selective peroxisome proliferator-activated receptor gamma modulator with distinct fat cell regulation properties.
    Fujimura T; Kimura C; Oe T; Takata Y; Sakuma H; Aramori I; Mutoh S
    J Pharmacol Exp Ther; 2006 Aug; 318(2):863-71. PubMed ID: 16682454
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A peroxisome proliferator-activated receptor alpha/gamma dual agonist with a unique in vitro profile and potent glucose and lipid effects in rodent models of type 2 diabetes and dyslipidemia.
    Reifel-Miller A; Otto K; Hawkins E; Barr R; Bensch WR; Bull C; Dana S; Klausing K; Martin JA; Rafaeloff-Phail R; Rafizadeh-Montrose C; Rhodes G; Robey R; Rojo I; Rungta D; Snyder D; Wilbur K; Zhang T; Zink R; Warshawsky A; Brozinick JT
    Mol Endocrinol; 2005 Jun; 19(6):1593-605. PubMed ID: 15831517
    [TBL] [Abstract][Full Text] [Related]  

  • 7. T2384, a novel antidiabetic agent with unique peroxisome proliferator-activated receptor gamma binding properties.
    Li Y; Wang Z; Furukawa N; Escaron P; Weiszmann J; Lee G; Lindstrom M; Liu J; Liu X; Xu H; Plotnikova O; Prasad V; Walker N; Learned RM; Chen JL
    J Biol Chem; 2008 Apr; 283(14):9168-76. PubMed ID: 18263587
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thiazolidinediones and rexinoids induce peroxisome proliferator-activated receptor-coactivator (PGC)-1alpha gene transcription: an autoregulatory loop controls PGC-1alpha expression in adipocytes via peroxisome proliferator-activated receptor-gamma coactivation.
    Hondares E; Mora O; Yubero P; Rodriguez de la Concepción M; Iglesias R; Giralt M; Villarroya F
    Endocrinology; 2006 Jun; 147(6):2829-38. PubMed ID: 16513826
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chebulagic acid from Terminalia chebula enhances insulin mediated glucose uptake in 3T3-L1 adipocytes via PPARγ signaling pathway.
    Shyni GL; Kavitha S; Indu S; Arya AD; Anusree SS; Vineetha VP; Vandana S; Sundaresan A; Raghu KG
    Biofactors; 2014; 40(6):646-57. PubMed ID: 25529897
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PPAR(gamma)/PGC-1(alpha) pathway in E-cadherin expression and motility of HepG2 cells.
    Lee HJ; Su Y; Yin PH; Lee HC; Chi CW
    Anticancer Res; 2009 Dec; 29(12):5057-63. PubMed ID: 20044617
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The potential insulin sensitizing and glucose lowering effects of a novel indole derivative in vitro and in vivo.
    Li YY; Wu HS; Tang L; Feng CR; Yu JH; Li Y; Yang YS; Yang B; He QJ
    Pharmacol Res; 2007 Oct; 56(4):335-43. PubMed ID: 17889553
    [TBL] [Abstract][Full Text] [Related]  

  • 12. INT131: a selective modulator of PPAR gamma.
    Motani A; Wang Z; Weiszmann J; McGee LR; Lee G; Liu Q; Staunton J; Fang Z; Fuentes H; Lindstrom M; Liu J; Biermann DH; Jaen J; Walker NP; Learned RM; Chen JL; Li Y
    J Mol Biol; 2009 Mar; 386(5):1301-11. PubMed ID: 19452630
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rational discovery of a novel interface for a coactivator in the peroxisome proliferator-activated receptor gamma: theoretical implications of impairment in type 2 diabetes mellitus.
    Shiraki T; Kodama TS; Jingami H; Kamiya N
    Proteins; 2005 Feb; 58(2):418-25. PubMed ID: 15558556
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of an In Vitro Screening Platform for the Identification of Partial PPARγ Agonists as a Source for Antidiabetic Lead Compounds.
    Porskjær Christensen L; Bahij El-Houri R
    Molecules; 2018 Sep; 23(10):. PubMed ID: 30248999
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modulation of energy deficiency in Huntington's disease via activation of the peroxisome proliferator-activated receptor gamma.
    Chiang MC; Chen CM; Lee MR; Chen HW; Chen HM; Wu YS; Hung CH; Kang JJ; Chang CP; Chang C; Wu YR; Tsai YS; Chern Y
    Hum Mol Genet; 2010 Oct; 19(20):4043-58. PubMed ID: 20668093
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PAT5A: a partial agonist of peroxisome proliferator-activated receptor gamma is a potent antidiabetic thiazolidinedione yet weakly adipogenic.
    Misra P; Chakrabarti R; Vikramadithyan RK; Bolusu G; Juluri S; Hiriyan J; Gershome C; Rajjak A; Kashireddy P; Yu S; Surapureddi S; Qi C; Zhu YJ; Rao MS; Reddy JK; Ramanujam R
    J Pharmacol Exp Ther; 2003 Aug; 306(2):763-71. PubMed ID: 12730351
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Glucose Sensor ChREBP Links De Novo Lipogenesis to PPARγ Activity and Adipocyte Differentiation.
    Witte N; Muenzner M; Rietscher J; Knauer M; Heidenreich S; Nuotio-Antar AM; Graef FA; Fedders R; Tolkachov A; Goehring I; Schupp M
    Endocrinology; 2015 Nov; 156(11):4008-19. PubMed ID: 26181104
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TNF-alpha reduces PGC-1alpha expression through NF-kappaB and p38 MAPK leading to increased glucose oxidation in a human cardiac cell model.
    Palomer X; Alvarez-Guardia D; Rodríguez-Calvo R; Coll T; Laguna JC; Davidson MM; Chan TO; Feldman AM; Vázquez-Carrera M
    Cardiovasc Res; 2009 Mar; 81(4):703-12. PubMed ID: 19038972
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel peroxisome proliferator-activated receptor (PPAR) gamma and PPARdelta ligands produce distinct biological effects.
    Berger J; Leibowitz MD; Doebber TW; Elbrecht A; Zhang B; Zhou G; Biswas C; Cullinan CA; Hayes NS; Li Y; Tanen M; Ventre J; Wu MS; Berger GD; Mosley R; Marquis R; Santini C; Sahoo SP; Tolman RL; Smith RG; Moller DE
    J Biol Chem; 1999 Mar; 274(10):6718-25. PubMed ID: 10037770
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Positive correlation between PPARgamma/PGC-1alpha and gamma-GCS in lungs of rats and patients with chronic obstructive pulmonary disease.
    Li J; Dai A; Hu R; Zhu L; Tan S
    Acta Biochim Biophys Sin (Shanghai); 2010 Sep; 42(9):603-14. PubMed ID: 20732852
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.